Pirmenol

13 interactions
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 11, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Arsenic Trioxide Arsenic Trioxide Injection Chloroquine Disopyramide Dolasetron Dolasetron Injection
13 Major
All (13) Major (13)

Major

Pirmenol Arsenic Trioxide Trisenox An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Pirmenol Arsenic Trioxide Injection Trisenox An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Pirmenol Chloroquine Aralen® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Pirmenol Disopyramide Norpace An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Pirmenol Dolasetron Anzemet Cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Pirmenol Dolasetron Injection Anzemet Cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Pirmenol Flecainide Tambocor® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Pirmenol Foscarnet Injection Foscavir An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Pirmenol Gemifloxacin Factive An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Pirmenol Isradipine DynaCirc® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Pirmenol Mefloquine Lariam® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Pirmenol Octreotide Bynfezia An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Pirmenol Octreotide Injection Bynfezia An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.